Quantcast

Tag Archives: diabetes

Furloughs could become law firm layoffs, report says

(feedough / Depositphotos.com)

Welcome to Monday, the 37th anniversary of the U.S. Supreme Court’s Arizona Governing Committee v. Norris decision that Title VII of the 1964 Civil Rights Act prohibits states from discriminating on the basis of sex in providing retirement benefits. Here ...

Read More »

Startup emocha to make push into chronic disease next year

Sebastian Seiguer, CEO of emocha Mobile Health. (Maximilian Franz / The Daily Record)

Following the announcement of a trial partnership to help diabetes patients, Baltimore telemedicine startup emocha Mobile Health plans to expand its scope into chronic disease. With a three-month trial with University of Maryland Health Partners working primarily with low-income diabetes ...

Read More »

Maryland doctors to increase diabetes training

(Lisa F. Young / Depositphotos.com)

The Maryland chapter of the American Diabetes Association will hold its first training for primary care providers, updating them on the latest association standards for the treatment of diabetes. While endocrinologists are the specialists who treat diabetes, 85 to 90 ...

Read More »

Md. biopharm to work with another firm on diabetes drug

Germantown-based Intrexon Corp., a synthetic biology firm, now has a research collaboration agreement with another company to work on treatments for diabetes and other health problems. Intrexon will work with Janssen Pharmaceutica NV, one of the Janssen pharmaceutical companies of ...

Read More »

FDA OKs first-of-a-kind diabetes drug from J&J

WASHINGTON — The Food and Drug Administration says it has approved a first-of-a-kind diabetes drug from Johnson & Johnson that uses a new method to lower blood sugar. The agency cleared J&J’s Invokana tablets for adults with Type 2 diabetes, ...

Read More »

GlaxoSmithKline wins takeover bid for Human Genome

U.K. drug maker GlaxoSmithKline has secured its takeover of longtime partner Human Genome Sciences after agreeing to pay more, a move to expand GSK’s drug portfolio in crucial areas: biologic drugs and treatments for the hundreds of millions of people ...

Read More »